Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 19/20 | 0.66 |
| ▸ | METAP1 | P53582 | 13/20 | 0.66 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6477350 | 0.92 | METAP2 (0.64) | METAP2METAP1 | |
| SCHEMBL6487082 | 0.90 | METAP2 (0.62) | METAP2METAP1 | |
| SCHEMBL6483137 | 0.90 | METAP2 (0.64) | METAP2METAP1 | |
| SCHEMBL6477730 | 0.89 | METAP2 (0.68) | METAP2METAP1 | |
| SCHEMBL6486949 | 0.89 | METAP2 (0.68) | METAP2METAP1TAS1R3TAS1R1 | |
| SCHEMBL6477144 | 0.89 | METAP2 (0.60) | METAP2METAP1 | |
| SCHEMBL6486021 | 0.88 | METAP2 (0.62) | METAP2METAP1 | |
| SCHEMBL6477302 | 0.88 | METAP2 (0.62) | METAP2METAP1 | |
| SCHEMBL6485509 | 0.87 | METAP2 (0.76) | METAP2METAP1 | |
| SCHEMBL6476801 | 0.87 | METAP2 (0.63) | METAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887863-B2 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES (US) | 2005-05-03 | — | — | US | claimed |
| EP-1272456-B1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2004-10-27 | — | — | EP | claimed |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBVIE INC. | 2004-08-26 | — | — | US | claimed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | claimed |
| US-6887863-B2 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1272456-B1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | METAP2 1/4885METAP1 2/4885TAS1R3 3632/4885 |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | METAP2 1/4885METAP1 2/4885TAS1R3 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.